Physician profile
Thomas Scharnitz
NPI 1881058113
$655.29
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $74.49 · 2021: $546 · 2022: $34.43.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $76.02 | 2021 | |
| Leo Pharma INC. | $74.49 | 2020 | |
| Sanofi-Aventis U.S. LLC | $72.50 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $64.11 | 2021 | |
| Janssen Biotech, INC. | $62.94 | 2021 | |
| Pfizer INC. | $61.02 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $61.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $47.48 | 2021 | |
| Abbvie INC. | $44.56 | 2021 | |
| Genzyme Corporation | $41.71 | 2021 | |
| Incyte Corporation | $36.16 | 2021-2022 | |
| Ucb, INC. | $13.30 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Scharnitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.